A Centers for Disease Control and Prevention (CDC) panel recommended ending the “pause” on Johnson & Johnson’s COVID-19 vaccine on Friday.
In 10-4 vote, with one abstention, the Advisory Committee on Immunization Practices (ACIP) recommended that the vaccine again be approved for all adults, deciding that the benefits outweighed the risks.The panel suggested that a warning label should be added to warn consumers of the rare blot clotting disorder that caused the single-dose vaccine to be temporarily suspended on April 13.
Among the 8 million who received doses of the vaccine,15 cases of the disorder have been identified, resulting in at least one death. The CDC will need to approve the ACIP recommendation before vaccinations resume.
This is a developing story and will be updated as more information becomes available.
